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Cutaneous allodynia (CA) is an abnormal pain in response to non-painful stimuli. In the present study, 
we sought to investigate the presence of CA, its associated factors, and its clinical implications in 
patients with cluster headache (CH). In this cross-sectional study, we analysed data from a prospective 
multicentre registry enrolling consecutive patients with CH. We identified CA during and between 
headache attacks using the 12-item Allodynia Symptom Checklist (ASC) administered during the CH 
bout period. Comorbid depression and anxiety were ascertained using the patient Health Questionnaire 
(PHQ-9) and the Generalized Anxiety Disorder (GAD-7) scales. Headache impact was evaluated 
using the Headache Impact Test-6 (HIT-6). Of 119 eligible patients, 48 and two (40.3% and 1.7%) had 
CA during and between headache attacks, respectively. In univariable analyses, total CH duration, 
major depressive disorder (MDD), and generalized anxiety disorder (GAD) were associated with CA 
during headache attack. They remained significantly associated with CA during headache attack 
in multivariable analyses. patients with CA during headache attack had higher headache impact 
(P = 0.002). A “50% responder” analysis showed no difference in outcome of acute and preventive 
treatment between patients with and without CA during headache attack. patients with CH commonly 
experienced CA during headache attack, but not between headache attacks. CA during headache attack 
was associated with disease duration, depression, and anxiety.
Cutaneous allodynia (CA) is a clinical manifestation of pain or discomfort in response to non-painful stimuli that 
occurs in up to 80% of patients with migraine1–4. Over the past two decades, CA in patients with migraine has 
piqued increasing interest among researchers, and many studies have explored its pathophysiology and clinical 
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implications. In particular, CA during a migraine attack is presently recognized as a surrogate marker of sensi-
tization of central pain-signalling neurons in the trigeminal nucleus caudalis5,6. Furthermore, the symptom has 
been associated with triptans inefficacy, depression, and migraine chronification, suggesting that it has more 
associations than somatic pain alone7–10.
Cluster headache (CH) is a relatively rare primary headache disorder characterized by recurrent attacks of 
severe headache centred in the ophthalmic division of the trigeminal nerve. It involves ipsilateral cranial auto-
nomic symptoms and has a relapsing–remitting course, with regular headache attacks occurring during the bout 
periods11,12. Despite some common points of pathophysiology, clinical manifestations, and treatment between 
migraine and CH, previous studies have shown inconsistent results with regard to the presence of CA in CH13–18. 
The first observation reported that 40% of CH patients were allodynic13, whereas quantitative sensory testing 
study found an opposite result, increased sensory thresholds to mechanical and thermal stimuli in CH patients15. 
In a recent largest study on this issue, 35.9% of patients with CH experienced CA during a headache attack, and 
CA was independently associated with depression19.
Regarding CA in CH, the present study sought to ascertain (1) the presence of CA among patients with CH in 
the Asian population, (2) the relation between CA and anxiety in patients with CH, (3) the association between 
CA severity and psychiatric comorbidities, and (4) the clinical implications of CA including headache impact and 
treatment response. Therefore, using a multicentre registry of patients with CH, we investigated the presence of 
CA during and between headache attacks, the factors associated with CA, the relationship between CA severity 
and psychiatric comorbidities, and the influence of CA on headache impact and treatment response.
Methods
study design and patients. This was a prospective, cross-sectional study that used data from the Korean 
Cluster Headache Registry, which is a prospective, multicentre registry of consecutive patients with CH aged ≥19 
years. The registry involves 15 hospitals across Korea—13 university hospitals (eight tertiary and five second-
ary referral) and two secondary referral general hospitals. The study protocol was approved by the local ethics 
committee or Institutional Review Board in each study hospital (Bundang Jesaeng General Hospital, Uijeongbu 
St.Mary’s Hospital, Chuncheon Sacred Heart Hospital, Samsung Medical Center, Eulji Hospital, Sacred Heart 
Hospital, Seoul Medical Center, Presbyterian Medical Center, Ewha Womans University Mokdong Hospital, 
Kangbuk Samsung Hospital, Korea University Kuro Hospital, Seoul St. Mary’s Hospital, Gyeongsang National 
University Hospital, Chung-Ang University Hospital, Seoul Paik Hospital, and Dongtan Sacred Heart Hospital) 
and conformed to the Declaration of Helsinki and Good Clinical Practice guidelines. All patients totally under-
stood the study proposal and provided informed written consent before their participation.
We analysed the data of patients enrolled between September 2016 and February 2018. CH was diagnosed 
by experienced headache neurologists using the clinical criteria found in the 3rd edition of the International 
Classification of Headache Disorder, Beta Version (ICHD-3β)20. Since our main research subject was the presence 
of CA, we included patients who enrolled during the bout period of CH. The exclusion criteria were as follows: 
(1) enrolment during remission period, (2) possible secondary cause, (3) no or incomplete response to allodynia 
questionnaire, (4) missing clinical variables, and (5) lack of follow-up visits.
Measurement. We used the 12-item Allodynia Symptom Checklist (ASC) to determine the presence of CA 
both during and between headache attacks4. Thus, the baseline questionnaire consisted of two ASCs. The item 
responses for each allodynia symptom were categorized as follows: “never,” “rarely,” “less than half the time,” and 
“half the time or more.” These responses were converted into scores as follows: 0 (never, rarely, or does not apply 
to me), 1 (less than half the time), and 2 (half the time or more). Thus, the total ASC score ranged from 0 to 24. 
Based this score, the patients were classified into four allodynia severity groups: no CA (0–2), mild CA (3–5), 
moderate CA (6–8), and severe CA (9–24)4. In terms of the presence of CA, the study patients were dichoto-
mously divided into a no CA (ASC score ≤2) group and a CA (ASC score ≥3) group.
We used the following clinical information in our analysis: demographic factors, social habits, headache 
characteristics, psychiatric comorbidity, headache impact, and treatment response. Psychiatric comorbidity was 
assessed using the Korean versions of the Patient Health Questionnaire 9-item scale (PHQ-9) and the Generalized 
Anxiety Disorder 7-item scale (GAD-7). Major depressive disorder (MDD) and generalized anxiety disorder 
(GAD) were identified in patients with PHQ-9 and GAD-7 scores of ≥10, respectively21. If patients had either 
MDD or GAD, they were considered as having a psychiatric comorbidity. Headache impact was evaluated using 
the Headache Impact Test-6 (HIT-6)22. The appropriate CH treatment was determined individually by each inves-
tigator, and treatment response was investigated at the follow-up visits. Treatment-response assessment of study 
patients was conducted during their follow-up reservations as a part of daily clinical practice. Study patients 
usually started both acute and preventive therapy right after the enrolment. Given action time of some preventive 
treatment (verapamil or lithium), we set the judgement point at least 2 weeks after an initial visit. Treatment out-
come was assessed using analysis of 50% responders, defined as any patient who showed ≥50% relief of headache 
attacks after acute treatment, or a ≥50% reduction in headache frequency after preventive treatment.
statistical analysis. Continuous variables are shown as means ± standard deviation, while categorical var-
iables are given as numbers (percentage). The chi-square, Fisher’s exact, or linear-by-linear association test was 
used to compare categorical variables. To identify factors associated with CA, we conducted logistic regression 
analyses. The results of the univariable analyses are given odds ratios (ORs) and 95% confidence intervals (CIs). 
Because age, female sex, comorbid migraine may be associated with allodynia, the multivariate models were 
adjusted for these variables, regardless of whether they showed statistical significance in the univariable analy-
ses8,19. All factors with P-values < 0.05 in the univariable analyses were considered potential covariates and were 
entered into the multivariable model. If any pair of potential covariates were closely correlated, we conducted 
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separate multivariable models. Independent CA variables were presented as multivariable-adjusted ORs (aORs) 
and 95% CIs. All statistical analyses were conducted using SPSS for Windows (version 18.0; IBM Corp., Armonk, 
NY, USA). All reported P-values are two-tailed, and those <0.05 were considered statistically significant.
Results
study patients. During the study period, 159 patients were prospectively enrolled in the registry. Forty 
patients were excluded because they had one or more of the exclusion criteria: enrolment during a remission 
period (n = 40), possible secondary cause (n = 2), no or incomplete response to allodynia questionnaire (n = 21), 
and missing clinical variables (n = 7). Therefore, we conducted the first analysis using data from 119 eligible 
patients. Next, we performed a treatment-response analysis after excluding seven patients who failed to show up 
to their follow-up reservations. With regards to headache classification, 101 patients (84.8%) definitely fulfilled 
the clinical criteria for first cluster period of CH (ICHD-3β code 3.1), while 18 patients (15.2%) were diagnosed 
as having probable CH (ICHD-3β code 3.5.1) and five (4.2%) were classified as having chronic CH. The mean age 
at enrolment was 38.5 ± 11.3 years, while that of CH onset was 30.1 ± 13.3 years, respectively (Table 1). Since 20 
patients (16.8%) were women, the male-to-female ratio was 4.95 to 1. Eighteen patients had a coexisting history 
of migraine (15.1%). Baseline characteristics of age, female sex, coexisting migraine history, total duration of CH 
illness, duration of cluster headache bout, attack duration, MDD, and GAD in patients who completed the ASC 
did not significantly differ from those of patients excluded due to incomplete response to the ASC.
presence of cutaneous allodynia in patients with cluster headache. The analysis of the presence 
of CA is summarized in Fig. 1. During headache attack, 40 (40.3%) patients had CA, while 22.7% experienced 
moderate-to-severe CA. Between headache attacks, mild CA was reported in two patients (1.7%).
Factors associated with cutaneous allodynia during headache attack. Factors that may be asso-
ciated with CA during headache attack were identified by applying demographics, clinical characteristics of CH, 
and psychiatric comorbidities (Table 1). Univariable analyses revealed that the total CH duration was significantly 
associated with CA during headache attack (OR: 1.07, 95% CI: 1.02–1.13). Headache attack frequency, attack 
duration, pain intensity, and duration of CH bout were not related to CA during headache attack. With regards to 
psychological aspects, comorbid MDD and GAD were significantly associated with CA during headache attack 
(OR: 2.67, 95% CI: 1.20–5.93 and OR: 3.48, 95% CI: 1.59–7.59, respectively).
In the multivariable models, the ORs of total duration of CH illness were significantly increased (OR: 1.08, 
95% CI: 1.02–1.13 in model 1; OR: 1.06, 95% CI: 1.01–1.12 in model 2; OR: 1.07, 95% CI: 1.01–1.13 in model 3; 
Table 2). MDD, GAD, and psychiatric comorbidity were also found to be significantly associated with CA during 
headache attack (OR: 2.37, 95% CI: 1.01–5.55 for MDD; OR: 2.74, 95% CI: 1.20–6.28 for GAD; OR: 2.91, 95% CI: 
1.30–6.52 for psychiatric comorbidity).
Association between stratum of total duration of CH illness and CA during headache attack was further exam-
ined in univariable and multivariable analyses (Table 3). Compared to total duration of CH illness ≤1 year, total 
duration of CH illness >10 years was associated with CA during headache attack in univariable analysis (OR: 
2.66, 95% CI: 1.01–7.03). The association tended to increase across the stratum of total duration of CH illness (P 
for trend = 0.019). The association remained significant after adjustment for potential covariates.
Total (n = 119) CA (n = 48) No CA (n = 71) OR (95% CI) P
Age, years 38.5 ± 11.3 39.2 ± 10.4 38.0 ± 11.8 1.00 (0.97–1.04) 0.588
Female sex, no. (%) 20 (16.8) 11 (22.9) 9 (12.7) 2.04 (0.77–5.40) 0.148
Body mass index, kg/m2 23.9 ± 3.1 23.8 ± 3.2 24.0 ± 3.0 0.97 (0.86–1.09) 0.687
Current smoking, no. (%) 54 (45.4) 25 (52.1) 29 (40.8) 1.57 (0.75–3.29) 0.228
Alcohol drinking, no. (%) 61 (51.3) 25 (52.1) 36 (50.7) 1.05 (0.50–2.19) 0.883
Coexisting migraine history, no. (%) 18 (15.1) 8 (16.7) 10 (14.1) 1.22 (0.44–3.35) 0.700
Onset age of cluster headache, years 30.1 ± 13.3 28.0 ± 13.2 31.5 ± 13.3 0.97 (0.95–1.00) 0.161
Total duration of CH illness, years 8.4 ± 8.1 11.2 ± 9.3 6.5 ± 6.7 1.07 (1.02–1.13) 0.003
Recurrent bout, no. (%) 96 (80.6) 39 (81.3) 57 (80.3) 1.06 (0.41–2.70) 0.896
Duration of cluster headache bout, weeks 10.3 ± 38.9 17.1 ± 60.1 5.8 ± 8.8 1.01 (0.99–1.03) 0.244
Attack frequency per day 2.2 ± 1.9 2.5 ± 2.4 2.0 ± 1.4 1.13 (0.93–1.36) 0.199
Attack duration, minutes 93.1 ± 62.8 89.5 ± 52.0 95.6 ± 69.4 0.99 (0.99–1.00) 0.602
Headache intensity (0–10 VAS) 8.9 ± 1.3 9.0 ± 1.2 8.9 ± 1.3 1.08 (0.81–1.45) 0.565
MDD, no. (%) 37 (31.1) 21 (43.8) 16 (22.5) 2.67 (1.20–5.93) 0.016
GAD, no. (%) 44 (37.0) 26 (54.2) 18 (25.4) 3.48 (1.59–7.59) 0.002
Psychiatric comorbidity (either MDD or GAD), no. (%) 55 (46.2) 31 (64.6) 24 (33.8) 3.57 (1.65–7.70) 0.001
Table 1. Baseline characteristics and univariable analysis on factors associated with cutaneous allodynia during 
headache attack. The data are shown as the mean ± standard deviation or number (percentage). Abbreviations: 
CA, cutaneous allodynia; CH, cluster headache; CI, confidence interval; GAD, generalized anxiety disorder; 
MDD, major depressive disorder; OR, odds ratio; VAS, visual analogue scale.
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The relationship between total duration of CH illness and CA was analysed by dividing the patients into two 
groups according to the presence of psychiatric comorbidity (Fig. 2). The proportion of CA during headache 
attack was increased according to the category of total duration of CH illness: 30.8% after ≤1 year, 26.7% between 
1 and ≤5 years, 36.0% between 5 and ≤10 years, and 60.5% after 10 years; P = 0.019. In patients without psychi-
atric comorbidity, there was a clear dose–response relationship between CA during headache attack and total 
duration of CH illness: 6.7% after ≤1 year, 15.0% between 1 and ≤5 years, 35.7% between 5 and ≤10 years, and 
53.3% after 10 years; P = 0.013.
Association between cutaneous allodynia severity during headache attack and psychiatric 
comorbidity. The proportions of patients with MDD, GAD, and psychiatric comorbidity were compared in 
terms of CA severity during headache attack (Fig. 3). The prevalences of MDD, GAD, and psychiatric comorbid-
ity were highest in patients with severe CA during headache attack (58.3%, 83.3%, and 91.7%, respectively). The 
prevalence of MDD increased with the CA severity during headache attack, although not significantly (P = 0.055). 
The prevalences of GAD and psychiatric comorbidities increased significantly with the CA severity during head-
ache attack (P < 0.001 and P = 0.001, respectively).
Cutaneous allodynia during headache attack and headache impact. The quartiles of the HIT-6 
scores were compared in terms of presence of CA during headache attack (Fig. 4). The prevalences of 3rd- and 
4th-quartile HIT-6 scores were significantly higher in patients with CA during headache attack sthan in those 
without (22.9% and 39.6% vs. 19.7% and 15.5%, respectively; P = 0.002).
Cutaneous allodynia during headache attack and treatment response. The 50% responder 
analysis is summarized in Table 4. The number of patients receiving each CH treatment was as follows: oxygen 
(n = 13), NSAIDs (n = 17), combined analgesics (n = 11), triptans (n = 78), oral corticosteroid (n = 53), occipital 
nerve block (n = 9), verapamil (n = 47), and lithium (n = 16). The treatment response did not differ significantly 
between patients with and without CA during headache attack in any of the CH treatment subgroups.
Discussion
In the present prospective study, CA during headache attack was present in 40.3% of patients with CH, whereas 
only 1.7% experienced CA between headache attacks. Total duration of CH illness, MDD, and GAD were inde-
pendently associated with CA during headache attack. Patients without psychiatric comorbidity showed a marked 
association between disease duration and CA during headache attack, and there was a dose–response relationship 
Figure 1. Presence of cutaneous allodynia during and between headache attacks in patients with cluster 
headache. Abbreviations: ASC, Allodynia Symptom Checklist; CA, cutaneous allodynia.
Model 1 Model 2 Model 3
aOR (95% CI) P aOR (95% CI) P aOR (95% CI) P
Age 1.00 (0.96–1.03) 0.886 1.00 (0.97–1.04) 0.745 1.00 (0.96–1.04) 0.842
Female sex 2.11 (0.72–6.13) 0.168 2.45 (0.84–7.17) 0.100 2.26 (0.77–6.60) 0.133
Coexisting migraine history 1.24 (0.40–3.82) 0.700 1.26 (0.41–3.85) 0.675 1.33 (0.43–4.09) 0.612
Total duration of CH illness (per year) 1.08 (1.02–1.13) 0.003 1.06 (1.01–1.12) 0.014 1.07 (1.01–1.13) 0.010
MDD 2.37 (1.01–5.55) 0.046
GAD 2.74 (1.20–6.28) 0.017
Psychiatric comorbidity (either MDD or GAD) 2.91 (1.30–6.52) 0.009
Table 2. Independent variables of cutaneous allodynia during headache attack. Age, female sex, coexisting 
migraine history, and potential variables (P < 0.10 at univariable analyses) were selected to develop 
multivariable models. MDD, GAD, and psychiatric comorbidity were entered into different models, because 
they were correlated each other. Abbreviations: aOR, multivariable-adjusted odds ratio; CH, cluster headache; 
CI, confidence interval; GAD, generalized anxiety disorder; MDD, major depressive disorder.
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between CA severity during headache attack and psychiatric comorbidity. Patients with CA during headache 
attack suffered from greater headache impact. However, there was no significant difference in treatment response 
between patients with and without CA during headache attack.
In line with the Dutch study, the results of the current study indicate that CA during headache attack occurs 
in about 40% of patients with CH19. This consistency of results is interesting because the two study populations 
differ greatly in terms of ethnicity and sociocultural environment. It follows that the presence of CA in CH is 
likely relatively consistent among different populations. In addition, it is important to note that both studies used 
the ASC-12 to evaluate the presence of CA, rather than quantitative sensory testing, which is the gold standard 
for determining allodynia. The ASC-12 has not been comprehensively validated in patients with CH, while quan-
titative sensory testing has. Nevertheless, the Dutch study reported an acceptable outcome in terms of external 
validation of the ASC-1219. Given that our results were analogous to those of the Dutch study, it is likely that the 
ASC-12 questionnaire could be used to determine the presence of CA in future studies on this topic. The current 
Univariable analysis Model 1 Model 2 Model 3
OR (95% CI) P aOR (95% CI) P aOR (95% CI) P aOR (95% CI) P
Stratum of total duration of CH illness
   ≤1 year reference reference reference reference
   1< and ≤5 years 0.89 (0.29–2.73) 0.843 1.05 (0.31–3.50) 0.935 0.92 (0.27–3.10) 0.901 1.11 (0.32–3.75) 0.865
   5< and ≤10 years 1.33 (0.43–4.08) 0.608 1.89 (0.57–6.28) 0.294 1.67 (0.50–5.56) 0.403 1.85 (0.55–6.21) 0.316
   >10 years 2.66 (1.01–7.03) 0.048 3.75 (1.31–10.73) 0.013 2.90 (1.01–8.30) 0.047 3.34 (1.17–9.58) 0.024
   P for trend 0.019 0.005 0.019 0.011
Table 3. Association of total duration of cluster headache illness with cutaneous allodynia during headache 
attack. Model 1: adjustment for age, female sex, coexisting migraine history, and MDD; Model 2: adjustment 
for age, female sex, coexisting migraine history, and GAD; Model 3: adjustment for age, female sex, coexisting 
migraine history, and psychiatric comorbidity (either MDD or GAD). Abbreviations: aOR, multivariable-
adjusted odds ratio; CH, cluster headache; CI, confidence interval; GAD, generalized anxiety disorder; MDD, 
major depressive disorder; OR, odds ratio.
Figure 2. Proportions of patients with cutaneous allodynia during headache attack according to total duration 
of cluster headache illness. Abbreviation: CH, cluster headache.
Figure 3. Proportions of patients with major depressive disorder, generalized anxiety disorder, and psychiatric 
comorbidity according to severity of cutaneous allodynia during headache attack. Abbreviations: CA, cutaneous 
allodynia; GAD, generalized anxiety disorder; MDD, major depressive disorder.
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study had an additional strength: we analysed the data of patients who responded to the questionnaire during a 
CH bout. This may have minimized the risk of recall bias in the questionnaire evaluation process.
With respect to the presence of CA between headache attacks (interictal CA), previous results have been 
inconsistent13,14,16,18. In the present study, only two patients (1.7%) experienced mild CA between headache 
attacks. The same patients had moderate-to-severe CA during headache attack, and their headache subtype was 
episodic CH. Neither had any coexisting migraine history or psychiatric comorbidity. These findings indicate that 
the major form of CA in patients with CH is acute allodynia during headache attack. Further studies are required 
to confirm our findings.
In the current study, we confirmed that CA is associated with both depression and anxiety in patients with CH, 
and that the frequencies of depression and anxiety increased with CA severity, partly corroborating the results of 
a population study of individuals who suffer migraines8. Notably, more than 90% of patients with severe CA had 
either depression or anxiety, suggesting that clinicians must consider psychological aspects in the management of 
patients with CH patients with CA. CA has been associated with comorbid affective disorders, perhaps because 
the conditions share a neuroanatomical site. In this regard, the prefrontal cortex and anterior cingulate cortex 
are thought to be the functional areas of the affective component of pain perception23. In particular, a previous 
functional MRI study showed that these areas were activated in response to virtual pain stimulation in patients 
with allodynia24. Furthermore, the substantia nigra pars compacta and ventral tegmental area are known as the 
action sites of multiple antidepressants. The trigeminal nucleus caudalis is adjacent to this site, which may explain 
the association between CA and depression8.
Previous studies have reported that cluster pain and ictal CA disappear in response to oxygen or triptans13,16,18. 
These results are somewhat contrary our expectation that CH patients with CA may have a lack of efficacy of 
acute treatment. In the present study, the presence of CA during headache attack did not significantly influence 
the outcome of acute or preventive therapy in patients with CH. Most patients were given preventive therapy at 
the same time treatment response was assessed, since they usually started both acute and preventive therapy after 
the enrolment. Therefore, when interpreting our results, we must remember that preventive therapy can affect the 
response to acute therapy and decrease allodynia25. Given that our assessment was a simple observation of daily 
clinical practice, the exact role of CA in CH treatment must be examined further in future investigations with an 
interventional design.
Previous investigations have been contradictory regarding the association between disease duration and allo-
dynia in CH13,14,17,19. However, in the present study, longer disease duration was clearly associated with the pres-
ence of CA during headache attack, and the multivariable models consistently demonstrated that disease duration 
was significantly associated with ictal CA. Patients suffered from CH for >10 years, compared to those for ≤1 
Figure 4. Headache impact between patients with and without cutaneous allodynia during headache attack. 
Abbreviations: HIT-6, Headache Impact Test-6; Q1, 1st quartile; Q2, 2nd quartile; Q3, 3rd quartile; Q4, 4th 
quartile.
CA (n = 48) No CA (n = 71) P*
Acute treatment
   Oxygen 7/7 (100.0) 3/6 (50.0) 0.070
   NSAIDs 6/6 (100.0) 10/11 (90.9) 1.000
   Combined analgesics 4/7 (57.1) 2/4 (50.0) 1.000
   Triptans 36/37 (97.3) 36/41 (87.8) 0.204
Preventive treatment
   Oral corticosteroid 26/29 (89.7) 23/24 (95.8) 0.617
   Occipital nerve block 3/4 (75.0) 4/5 (80.0) 1.000
   Verapamil 22/24 (91.7) 18/23 (78.3) 0.245
   Lithum 8/10 (80.0) 3/6 (50.0) 0.299
Table 4. Treatment response analysis: numbers and proportions of 50% percent responder to cluster headache 
treatment between patients with and without cutaneous allodynia during headache attack. The data are shown 
as the number (percentage). *Comparison of the proportions of 50% percent responder between patients with 
and without cutaneous allodynia during headache attack. Abbreviations: CA, cutaneous allodynia; NSAIDs, 
nonsteroidal anti-inflammatory drugs.
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year, were at the risk of having ictal CA (OR: 3.34, 95% CI: 1.17–9.58 in multivariable model 3). These results sug-
gest that CA in patients with CH is a clinical consequence of time-dependent processes in central pain signalling 
neuron13,14. Interestingly, this association became more noticeable in patients without psychiatric comorbidities. 
Meanwhile, the prevalence of CA during headache attack was ≥60% in patients with psychiatric comorbidities, 
even when the disease duration was short ≤1 year. Furthermore, CA tended to be more prevalent in patients with 
psychiatric comorbidity than in those without (56.3% vs. 26.5%). To summarise, allodynia in patients with CH 
may have a more intricate underlying mechanism involving central trigeminovascular neurons and higher corti-
cal centres related to affective function and pain perception, as shown in previous neuroimaging studies23,24,26–28.
There were some limitations to our study. Firstly, since the data were based on a multicentre, hospital-based 
registry, there may be a risk of selection bias. However, given the prevalence of CH in population studies (0.1–
0.3%), multicentre enrolment may be the optimal design to reduce the risk11,12. Secondly, the study may have 
lacked statistical power because the sample size was modest. Thirdly, the study enrolled only Korean patients. 
There is considerable dissimilarity between Western and Asian populations with CH29–31. Our results should 
be interpreted with this in mind. Fourthly, the proportion of patients with chronic CH was only 4.2% (n = 5) 
in our data. Of these, three patients had CA during headache attack, which was not significantly higher than in 
patients with episodic CH (60.0% vs. 39.5%; P = 0.392). Consequently, it was impossible to explore the relation-
ship between CH subtype and CA in our study. Fifthly, despite the fact that we found a significant association 
between disease duration and ictal allodynia, total clustered periods or accumulated burden of cluster headache 
attacks might be other explanatory variables. However, we could not ascertain the association of those variables 
with ictal CA, due to a lack of data, which should be investigated in future studies. Finally, we used the ICHD-3β 
in the current study. There were some changes in the clinical criteria for CH between the ICHD-3β and the 
ICHD-3 final version. In this regard, the use of the ICHD-3β version may have led to some discrepancies32.
Conclusions
We can confirm that a significant proportion of CH patients experience CA during headache attack, but rarely 
between headache attacks. The presence of CA was associated with disease duration and psychiatric comorbidity 
in patients with CH.
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